Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3529]

Researchers develop universal MHC molecules that can be produced rapidly at scale

Researchers develop universal MHC molecules that can be produced rapidly at scale

Immunotherapy for blood cancer: Remote destruction of tumour cells demonstrated

Immunotherapy for blood cancer: Remote destruction of tumour cells demonstrated

Study uncovers how B cells react to skin cancer

Study uncovers how B cells react to skin cancer

ASCO 2023: Personalised vaccines may revolutionise cancer treatment

ASCO 2023: Personalised vaccines may revolutionise cancer treatment

Some intestinal T cells can hinder cancer immunotherapy, while others can enhance it

Some intestinal T cells can hinder cancer immunotherapy, while others can enhance it

Dual immunotherapy shows promise to treat recurrent or metastatic nasopharyngeal cancer

Dual immunotherapy shows promise to treat recurrent or metastatic nasopharyngeal cancer

ASCO 2023: Radiotherapy may not be necessary after chemoimmunotherapy for primary mediastinal B-cell lymphoma

ASCO 2023: Radiotherapy may not be necessary after chemoimmunotherapy for primary mediastinal B-cell lymphoma

ASCO 2023: Targeted therapy achieves responses across multiple cancer types with FGFR alterations

ASCO 2023: Targeted therapy achieves responses across multiple cancer types with FGFR alterations

ASCO 2023: Ciltacabtagene autoleucel reduces risk of disease progression by 74% in multiple myeloma after lenalidomide stops working

ASCO 2023: Ciltacabtagene autoleucel reduces risk of disease progression by 74% in multiple myeloma after...

ASCO 2023: Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer

ASCO 2023: Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced...

More from ecancer